Variability in drug metabolism involving CYP may also play a role in the risk of developing SJS/TEN, as patients who have a slower drug metabolism related to CYP variants can develop adverse drug reactions [35]. This evidence concerns the gene PPIG and toxic epidermal necrolysis.